Zhonghua Liu Xing Bing Xue Za Zhi. 2026 Jan 10;47(1):105-112. doi: 10.3760/cma.j.cn112338-20250722-00514.
ABSTRACT
Objective: To evaluate the performance of blocking the mother to child transmission of HBV in Jiangsu Province, to standardize the practice of blocking the mother to child transmission of HBV. Methods: Five counties (districts) were selected in northern, central and southern Jiangsu; the local data of maternal HBV screening and blocking mother to child transmission of HBV during 2021-2023 were extracted from relevant information systems. Chi-square test, Cochran-Armitage test and Firth’s penalized likelihood logistic regression model were used for statistical analyses. Results: From 2021 to 2023, a total of 63 805 pregnant women were surveyed in HBV screening, the HBsAg positive rate was 4.46%. In the positive women, 18.46% were at high-risk for mother to child transmission of HBV indicated by HBeAg or HBV-DNA levels; the rate of antiviral therapy during pregnancy increased from 33.78% in 2021 to 82.20% in 2023 (P<0.001). In 2 844 HBV-exposed live-born infants, the annual timely injection rates of hepatitis B immune globulin exceeded 98.30% each year (P=0.627), and the annual timely injection rate of hepetitis B vaccine birth dose increased from 95.25% in 2021 to 99.12% in 2023 (P<0.001). The annual post-vaccination serological test rate in HBV-exposed infants increased from 68.83% in 2021 to 92.82% in 2023 (P<0.001). In the post-vaccination serological test of 2 343 children, the annual HBsAb negative rate fell from 18.59% in 2021 to 6.92% in 2023 (P<0.001). Eight cases of blocking failure were identified (0.34%), the blocking failure rate in the pregnant women at high risk was 1.65%. Multivariate analysis revealed that the risk for blocking failure was 6.75 times (aOR=6.75,95%CI: 1.46-64.47) higher in high-risk pregnant women who received no antiviral therapy than in those who received antiviral therapy during pregnancy. Conclusions: From 2021 to 2023, the measures of blocking the mother to child transmission of HBV in Jiangsu is effective. Antiviral therapy for pregnant women at high risk is the key determinant of success. In the blocking transmission practice, it is necessary to increase the antiviral treatment rate in pregnant women at high-risk, further standardize the post-vaccination serological test procedures and strengthen the booster vaccination in HBsAb-negative children.
PMID:41566272 | DOI:10.3760/cma.j.cn112338-20250722-00514
